Next Article in Journal
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
Next Article in Special Issue
Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy
Previous Article in Journal
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
Previous Article in Special Issue
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
Brief Report

Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer

1
Department of Nuclear Medicine with PET-Center, Clinic Ottakring (Wilhelminenspital), 1160 Vienna, Austria
2
Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
3
Department of Radiology and Nuclear Medicine, Hanusch Hospital, 1160 Vienna, Austria
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 4167-4173; https://doi.org/10.3390/curroncol28050353
Received: 23 August 2021 / Revised: 4 October 2021 / Accepted: 13 October 2021 / Published: 15 October 2021
(This article belongs to the Special Issue New Frontiers in Prostate Cancer Diagnosis and Treatment)
Introduction: the diagnostic performance of [64Cu]-DOTAGA-PSMA PET–CT imaging was compared retrospectively to [18F]-PSMA PET–CT in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local and possible metastatic disease. Methods: We retrospectively selected a total of 100 patients, who were consecutively examined in our department, with biochemical recurrence after radical prostatectomy or who had progressive local and possible metastatic disease in the last 3 months prior to this investigation. All patients were examined with a dedicated PET–CT scanner (Biograph; Siemens Healthineers). A total of 250 MBq (3.5 MBq per kg bodyweight, range 230–290 MBq) of [64Cu]-DOTAGA-PSMA or [18-F]-PSMA was applied intravenously. PET images were performed 1 h post-injection (skull base to mid-thigh). The maximum standardized uptake values (SUVmax) of PSMA-positive lesions and the mean standardized uptake value (SUVmean) of the right liver lobe were measured. Results: All but 9/50 of the patients (18%; PSA range: 0.01–0.7 µg/L) studied with [64Cu]-DOTAGA-PSMA and 6/50 of the ones (12%; PSA range: 0.01–4.2) studied with [18F]-PSMA had at least one positive PSMA lesion shown by PET–CT. The total number of lesions was higher with [64Cu]-DOTAGA-PSMA (209 vs. 191); however, the median number of lesions was one for [64Cu]-DOTAGA-PSMA and two for [18F]-PSMA. Interestingly, the median SUVmean of the right liver lobe was slightly higher for [18F]-PSMA (11.8 vs. 8.9). Conclusions: [64Cu]-DOTAGA-PSMA and [18F]-PSMA have comparable detection rates for the assessment of residual disease in patients with recurrent or primary progressive prostate cancer. The uptake in the liver is moderately different, and therefore at least the SUVs of the lesions in both studies would not be comparable. View Full-Text
Keywords: [64Cu]/[18F] PSMA; oncology; prostate cancer; PSMA positron emission; tomography/computed tomography (PET–CT); prostate-specific membrane; antigen (PSMA) [64Cu]/[18F] PSMA; oncology; prostate cancer; PSMA positron emission; tomography/computed tomography (PET–CT); prostate-specific membrane; antigen (PSMA)
Show Figures

Figure 1

MDPI and ACS Style

Mirzaei, S.; Lipp, R.; Zandieh, S.; Leisser, A. Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer. Curr. Oncol. 2021, 28, 4167-4173. https://doi.org/10.3390/curroncol28050353

AMA Style

Mirzaei S, Lipp R, Zandieh S, Leisser A. Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer. Current Oncology. 2021; 28(5):4167-4173. https://doi.org/10.3390/curroncol28050353

Chicago/Turabian Style

Mirzaei, Siroos, Rainer Lipp, Shahin Zandieh, and Asha Leisser. 2021. "Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer" Current Oncology 28, no. 5: 4167-4173. https://doi.org/10.3390/curroncol28050353

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop